APO Research
Talk to an analyst

APO RESEARCH · REPORT

Filgrastim and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032

29 December 2025207 pages

Choose your research edition.

Industry ResearchFilgrastim and Biosimilars Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Filgrastim and Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Filgrastim and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Filgrastim and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Filgrastim and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Filgrastim and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Filgrastim and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Filgrastim and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Filgrastim and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Filgrastim and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Filgrastim and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Filgrastim and Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Filgrastim and Biosimilars Segment by Company

Changchun GeneScience Pharmaceutical

CSPC Baike Biopharma

Shanghai Sunway Biotech

Amoytop Biotech

Qilu Pharmaceutical

Kexing Biopharm

Jiangsu Wuzhong Pharmaceutical

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

Chengdu Institute of Biological Products

SL Pharm

Teva

Tanvex BioPharma

Sandoz

Pfizer

Kashiv BioSciences

Amgen

Filgrastim and Biosimilars Segment by Type

Single-use Vials

Prefilled Syringes

Filgrastim and Biosimilars Segment by Application

Hospital and Clinic

Pharmacy

Other

Filgrastim and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Filgrastim and Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Filgrastim and Biosimilars sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Filgrastim and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Single-use Vials Major Manufacturers Table 3. Prefilled Syringes Major Manufacturers Table 4. Global Filgrastim and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital and Clinic Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Filgrastim and Biosimilars Industry Trends Table 9. Filgrastim and Biosimilars Industry Drivers Table 10. Filgrastim and Biosimilars Industry Opportunities and Challenges Table 11. Filgrastim and Biosimilars Industry Restraints Table 12. Global Filgrastim and Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Filgrastim and Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Filgrastim and Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2026) Table 16. Global Filgrastim and Biosimilars Revenue Market Share by Region (2027-2032) Table 17. Global Filgrastim and Biosimilars Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units) Table 19. Global Filgrastim and Biosimilars Sales by Region (2027-2032) & (K Units) Table 20. Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2026) Table 21. Global Filgrastim and Biosimilars Sales Market Share by Region (2027-2032) Table 22. Global Filgrastim and Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Filgrastim and Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Filgrastim and Biosimilars Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 26. Global Filgrastim and Biosimilars Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Filgrastim and Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Filgrastim and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Filgrastim and Biosimilars Manufacturers, Product Type & Application Table 30. Global Filgrastim and Biosimilars Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Filgrastim and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Filgrastim and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026) Table 37. Global Filgrastim and Biosimilars Revenue Market Share by Type (2027-2032) Table 38. Global Filgrastim and Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 40. Global Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 41. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026) Table 42. Global Filgrastim and Biosimilars Sales Market Share by Type (2027-2032) Table 43. Global Filgrastim and Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 44. Global Filgrastim and Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 45. Global Filgrastim and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2026) Table 49. Global Filgrastim and Biosimilars Revenue Market Share by Application (2027-2032) Table 50. Global Filgrastim and Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Global Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 53. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2026) Table 54. Global Filgrastim and Biosimilars Sales Market Share by Application (2027-2032) Table 55. Global Filgrastim and Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 56. Global Filgrastim and Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 57. Changchun GeneScience Pharmaceutical Company Information Table 58. Changchun GeneScience Pharmaceutical Business Overview Table 59. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 61. Changchun GeneScience Pharmaceutical Recent Development Table 62. CSPC Baike Biopharma Company Information Table 63. CSPC Baike Biopharma Business Overview Table 64. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio Table 66. CSPC Baike Biopharma Recent Development Table 67. Shanghai Sunway Biotech Company Information Table 68. Shanghai Sunway Biotech Business Overview Table 69. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio Table 71. Shanghai Sunway Biotech Recent Development Table 72. Amoytop Biotech Company Information Table 73. Amoytop Biotech Business Overview Table 74. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Amoytop Biotech Filgrastim and Biosimilars Product Portfolio Table 76. Amoytop Biotech Recent Development Table 77. Qilu Pharmaceutical Company Information Table 78. Qilu Pharmaceutical Business Overview Table 79. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 81. Qilu Pharmaceutical Recent Development Table 82. Kexing Biopharm Company Information Table 83. Kexing Biopharm Business Overview Table 84. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Kexing Biopharm Filgrastim and Biosimilars Product Portfolio Table 86. Kexing Biopharm Recent Development Table 87. Jiangsu Wuzhong Pharmaceutical Company Information Table 88. Jiangsu Wuzhong Pharmaceutical Business Overview Table 89. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 91. Jiangsu Wuzhong Pharmaceutical Recent Development Table 92. North China Pharmaceutical Company Information Table 93. North China Pharmaceutical Business Overview Table 94. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 96. North China Pharmaceutical Recent Development Table 97. Hangzhou Jiuyuan Gene Engineering Company Information Table 98. Hangzhou Jiuyuan Gene Engineering Business Overview Table 99. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio Table 101. Hangzhou Jiuyuan Gene Engineering Recent Development Table 102. Harbin Pharmaceutical Group Company Information Table 103. Harbin Pharmaceutical Group Business Overview Table 104. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio Table 106. Harbin Pharmaceutical Group Recent Development Table 107. Chengdu Institute of Biological Products Company Information Table 108. Chengdu Institute of Biological Products Business Overview Table 109. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio Table 111. Chengdu Institute of Biological Products Recent Development Table 112. SL Pharm Company Information Table 113. SL Pharm Business Overview Table 114. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. SL Pharm Filgrastim and Biosimilars Product Portfolio Table 116. SL Pharm Recent Development Table 117. Teva Company Information Table 118. Teva Business Overview Table 119. Teva Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Teva Filgrastim and Biosimilars Product Portfolio Table 121. Teva Recent Development Table 122. Tanvex BioPharma Company Information Table 123. Tanvex BioPharma Business Overview Table 124. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio Table 126. Tanvex BioPharma Recent Development Table 127. Sandoz Company Information Table 128. Sandoz Business Overview Table 129. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sandoz Filgrastim and Biosimilars Product Portfolio Table 131. Sandoz Recent Development Table 132. Pfizer Company Information Table 133. Pfizer Business Overview Table 134. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Pfizer Filgrastim and Biosimilars Product Portfolio Table 136. Pfizer Recent Development Table 137. Kashiv BioSciences Company Information Table 138. Kashiv BioSciences Business Overview Table 139. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio Table 141. Kashiv BioSciences Recent Development Table 142. Amgen Company Information Table 143. Amgen Business Overview Table 144. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Amgen Filgrastim and Biosimilars Product Portfolio Table 146. Amgen Recent Development Table 147. North America Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 150. North America Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 151. North America Filgrastim and Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 152. North America Filgrastim and Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 153. North America Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 156. North America Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 157. North America Filgrastim and Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 158. North America Filgrastim and Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 159. North America Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Filgrastim and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. North America Filgrastim and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. North America Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 163. North America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 164. North America Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 165. North America Filgrastim and Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 166. North America Filgrastim and Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 167. United States Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 168. Canada Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 169. Mexico Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 170. Europe Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 173. Europe Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 174. Europe Filgrastim and Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 175. Europe Filgrastim and Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 176. Europe Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 177. Europe Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 178. Europe Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 179. Europe Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 180. Europe Filgrastim and Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 181. Europe Filgrastim and Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 182. Europe Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Europe Filgrastim and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Europe Filgrastim and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Europe Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 186. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 187. Europe Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 188. Europe Filgrastim and Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 189. Europe Filgrastim and Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 190. Germany Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 191. France Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 192. U.K. Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 193. Italy Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 194. Russia Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 195. Spain Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 197. Switzerland Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 198. Sweden Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 199. Poland Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 200. China Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 201. China Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 202. China Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 203. China Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 204. China Filgrastim and Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 205. China Filgrastim and Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 206. China Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 207. China Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 208. China Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 209. China Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 210. China Filgrastim and Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 211. China Filgrastim and Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 212. Asia Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 213. Asia Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 214. Asia Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 215. Asia Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 216. Asia Filgrastim and Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 217. Asia Filgrastim and Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 218. Asia Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 219. Asia Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 220. Asia Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 221. Asia Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 222. Asia Filgrastim and Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 223. Asia Filgrastim and Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 224. Asia Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. Asia Filgrastim and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. Asia Filgrastim and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. Asia Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 228. Asia Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 229. Asia Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 230. Asia Filgrastim and Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 231. Asia Filgrastim and Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 232. Japan Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 233. South Korea Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 234. India Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 235. Australia Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 236. Taiwan Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 237. Southeast Asia Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 238. SAMEA Filgrastim and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 239. SAMEA Filgrastim and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 240. SAMEA Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 241. SAMEA Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 242. SAMEA Filgrastim and Biosimilars Sales Price by Type (2021-2026) & (US$/Unit) Table 243. SAMEA Filgrastim and Biosimilars Sales Price by Type (2027-2032) & (US$/Unit) Table 244. SAMEA Filgrastim and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 245. SAMEA Filgrastim and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 246. SAMEA Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 247. SAMEA Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 248. SAMEA Filgrastim and Biosimilars Sales Price by Application (2021-2026) & (US$/Unit) Table 249. SAMEA Filgrastim and Biosimilars Sales Price by Application (2027-2032) & (US$/Unit) Table 250. SAMEA Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. SAMEA Filgrastim and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. SAMEA Filgrastim and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. SAMEA Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 254. SAMEA Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 255. SAMEA Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 256. SAMEA Filgrastim and Biosimilars Sales Price by Country (2021-2026) & (US$/Unit) Table 257. SAMEA Filgrastim and Biosimilars Sales Price by Country (2027-2032) & (US$/Unit) Table 258. Brazil Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 259. Argentina Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 260. Chile Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 261. Colombia Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 262. Peru Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 263. Saudi Arabia Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 264. Israel Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 265. UAE Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 266. Turkey Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 267. Iran Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 268. Egypt Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Table 269. Key Raw Materials Table 270. Raw Materials Key Suppliers Table 271. Filgrastim and Biosimilars Distributors List Table 272. Filgrastim and Biosimilars Customers List Table 273. Research Programs/Design for This Report Table 274. Authors List of This Report Table 275. Secondary Sources Table 276. Primary Sources List of Figures Figure 1. Filgrastim and Biosimilars Image Figure 2. Global Filgrastim and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Filgrastim and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Single-use Vials Image Figure 5. Prefilled Syringes Image Figure 6. Global Filgrastim and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Filgrastim and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital and Clinic Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Filgrastim and Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 13. Global Filgrastim and Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Filgrastim and Biosimilars Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2032) Figure 16. Global Filgrastim and Biosimilars Sales (2021-2032) & (K Units) Figure 17. Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Filgrastim and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 20. Europe Filgrastim and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 21. China Filgrastim and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Filgrastim and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Filgrastim and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 24. Global Filgrastim and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Filgrastim and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Filgrastim and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Filgrastim and Biosimilars Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032) Figure 30. Global Filgrastim and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Filgrastim and Biosimilars Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032) Figure 33. Global Filgrastim and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Filgrastim and Biosimilars Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032) Figure 36. Global Filgrastim and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Filgrastim and Biosimilars Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032) Figure 39. North America Filgrastim and Biosimilars Revenue Share by Type (2021-2032) Figure 40. North America Filgrastim and Biosimilars Sales Share by Type (2021-2032) Figure 41. North America Filgrastim and Biosimilars Revenue Share by Application (2021-2032) Figure 42. North America Filgrastim and Biosimilars Sales Share by Application (2021-2032) Figure 43. North America Filgrastim and Biosimilars Revenue Share by Country (2021-2032) Figure 44. North America Filgrastim and Biosimilars Sales Share by Country (2021-2032) Figure 45. Europe Filgrastim and Biosimilars Revenue Share by Type (2021-2032) Figure 46. Europe Filgrastim and Biosimilars Sales Share by Type (2021-2032) Figure 47. Europe Filgrastim and Biosimilars Revenue Share by Application (2021-2032) Figure 48. Europe Filgrastim and Biosimilars Sales Share by Application (2021-2032) Figure 49. Europe Filgrastim and Biosimilars Revenue Share by Country (2021-2032) Figure 50. Europe Filgrastim and Biosimilars Sales Share by Country (2021-2032) Figure 51. China Filgrastim and Biosimilars Revenue Share by Type (2021-2032) Figure 52. China Filgrastim and Biosimilars Sales Share by Type (2021-2032) Figure 53. China Filgrastim and Biosimilars Revenue Share by Application (2021-2032) Figure 54. China Filgrastim and Biosimilars Sales Share by Application (2021-2032) Figure 55. Asia Filgrastim and Biosimilars Revenue Share by Type (2021-2032) Figure 56. Asia Filgrastim and Biosimilars Sales Share by Type (2021-2032) Figure 57. Asia Filgrastim and Biosimilars Revenue Share by Application (2021-2032) Figure 58. Asia Filgrastim and Biosimilars Sales Share by Application (2021-2032) Figure 59. Asia Filgrastim and Biosimilars Revenue Share by Country (2021-2032) Figure 60. Asia Filgrastim and Biosimilars Sales Share by Country (2021-2032) Figure 61. SAMEA Filgrastim and Biosimilars Revenue Share by Type (2021-2032) Figure 62. SAMEA Filgrastim and Biosimilars Sales Share by Type (2021-2032) Figure 63. SAMEA Filgrastim and Biosimilars Revenue Share by Application (2021-2032) Figure 64. SAMEA Filgrastim and Biosimilars Sales Share by Application (2021-2032) Figure 65. SAMEA Filgrastim and Biosimilars Revenue Share by Country (2021-2032) Figure 66. SAMEA Filgrastim and Biosimilars Sales Share by Country (2021-2032) Figure 67. Filgrastim and Biosimilars Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Filgrastim and Biosimilars Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Single-use Vials
  • Prefilled Syringes
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Wuzhong Pharmaceutical
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • Chengdu Institute of Biological Products
  • SL Pharm
  • Teva
  • Tanvex BioPharma
  • Sandoz
  • Pfizer
  • Kashiv BioSciences
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Filgrastim and Biosimilars Market by Type
  3. 1.2.1 Global Filgrastim and Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Single-use Vials
  5. 1.2.3 Prefilled Syringes
  6. 1.3 Filgrastim and Biosimilars Market by Application
  7. 1.3.1 Global Filgrastim and Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital and Clinic
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Filgrastim and Biosimilars Market Dynamics
  1. 2.1 Filgrastim and Biosimilars Industry Trends
  2. 2.2 Filgrastim and Biosimilars Industry Drivers
  3. 2.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Filgrastim and Biosimilars Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Filgrastim and Biosimilars Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Filgrastim and Biosimilars Revenue by Region
  3. 3.2.1 Global Filgrastim and Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Filgrastim and Biosimilars Revenue by Region (2021-2026)
  5. 3.2.3 Global Filgrastim and Biosimilars Revenue by Region (2027-2032)
  6. 3.2.4 Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Filgrastim and Biosimilars Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Filgrastim and Biosimilars Sales by Region
  9. 3.4.1 Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Filgrastim and Biosimilars Sales by Region (2021-2026)
  11. 3.4.3 Global Filgrastim and Biosimilars Sales by Region (2027-2032)
  12. 3.4.4 Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Filgrastim and Biosimilars Revenue by Manufacturers
  2. 4.1.1 Global Filgrastim and Biosimilars Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Filgrastim and Biosimilars Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Filgrastim and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Filgrastim and Biosimilars Sales by Manufacturers
  6. 4.2.1 Global Filgrastim and Biosimilars Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Filgrastim and Biosimilars Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Filgrastim and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Filgrastim and Biosimilars Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Filgrastim and Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Filgrastim and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Filgrastim and Biosimilars Manufacturers, Product Type & Application
  13. 4.7 Global Filgrastim and Biosimilars Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Filgrastim and Biosimilars Market CR5 and HHI
  16. 4.8.2 2025 Filgrastim and Biosimilars Tier 1, Tier 2, and Tier 3
5 Filgrastim and Biosimilars Market by Type
  1. 5.1 Global Filgrastim and Biosimilars Revenue by Type
  2. 5.1.1 Global Filgrastim and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Filgrastim and Biosimilars Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Filgrastim and Biosimilars Sales by Type
  6. 5.2.1 Global Filgrastim and Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Filgrastim and Biosimilars Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032)
  9. 5.3 Global Filgrastim and Biosimilars Price by Type
6 Filgrastim and Biosimilars Market by Application
  1. 6.1 Global Filgrastim and Biosimilars Revenue by Application
  2. 6.1.1 Global Filgrastim and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Filgrastim and Biosimilars Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Filgrastim and Biosimilars Sales by Application
  6. 6.2.1 Global Filgrastim and Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Filgrastim and Biosimilars Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032)
  9. 6.3 Global Filgrastim and Biosimilars Price by Application
7 Company Profiles
  1. 7.1 Changchun GeneScience Pharmaceutical
  2. 7.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 7.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 7.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  6. 7.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 7.2 CSPC Baike Biopharma
  8. 7.2.1 CSPC Baike Biopharma Company Information
  9. 7.2.2 CSPC Baike Biopharma Business Overview
  10. 7.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
  12. 7.2.5 CSPC Baike Biopharma Recent Developments
  13. 7.3 Shanghai Sunway Biotech
  14. 7.3.1 Shanghai Sunway Biotech Company Information
  15. 7.3.2 Shanghai Sunway Biotech Business Overview
  16. 7.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
  18. 7.3.5 Shanghai Sunway Biotech Recent Developments
  19. 7.4 Amoytop Biotech
  20. 7.4.1 Amoytop Biotech Company Information
  21. 7.4.2 Amoytop Biotech Business Overview
  22. 7.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
  24. 7.4.5 Amoytop Biotech Recent Developments
  25. 7.5 Qilu Pharmaceutical
  26. 7.5.1 Qilu Pharmaceutical Company Information
  27. 7.5.2 Qilu Pharmaceutical Business Overview
  28. 7.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  30. 7.5.5 Qilu Pharmaceutical Recent Developments
  31. 7.6 Kexing Biopharm
  32. 7.6.1 Kexing Biopharm Company Information
  33. 7.6.2 Kexing Biopharm Business Overview
  34. 7.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
  36. 7.6.5 Kexing Biopharm Recent Developments
  37. 7.7 Jiangsu Wuzhong Pharmaceutical
  38. 7.7.1 Jiangsu Wuzhong Pharmaceutical Company Information
  39. 7.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
  40. 7.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  42. 7.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
  43. 7.8 North China Pharmaceutical
  44. 7.8.1 North China Pharmaceutical Company Information
  45. 7.8.2 North China Pharmaceutical Business Overview
  46. 7.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  48. 7.8.5 North China Pharmaceutical Recent Developments
  49. 7.9 Hangzhou Jiuyuan Gene Engineering
  50. 7.9.1 Hangzhou Jiuyuan Gene Engineering Company Information
  51. 7.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  52. 7.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
  54. 7.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  55. 7.10 Harbin Pharmaceutical Group
  56. 7.10.1 Harbin Pharmaceutical Group Company Information
  57. 7.10.2 Harbin Pharmaceutical Group Business Overview
  58. 7.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
  60. 7.10.5 Harbin Pharmaceutical Group Recent Developments
  61. 7.11 Chengdu Institute of Biological Products
  62. 7.11.1 Chengdu Institute of Biological Products Company Information
  63. 7.11.2 Chengdu Institute of Biological Products Business Overview
  64. 7.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
  66. 7.11.5 Chengdu Institute of Biological Products Recent Developments
  67. 7.12 SL Pharm
  68. 7.12.1 SL Pharm Company Information
  69. 7.12.2 SL Pharm Business Overview
  70. 7.12.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
  72. 7.12.5 SL Pharm Recent Developments
  73. 7.13 Teva
  74. 7.13.1 Teva Company Information
  75. 7.13.2 Teva Business Overview
  76. 7.13.3 Teva Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Teva Filgrastim and Biosimilars Product Portfolio
  78. 7.13.5 Teva Recent Developments
  79. 7.14 Tanvex BioPharma
  80. 7.14.1 Tanvex BioPharma Company Information
  81. 7.14.2 Tanvex BioPharma Business Overview
  82. 7.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
  84. 7.14.5 Tanvex BioPharma Recent Developments
  85. 7.15 Sandoz
  86. 7.15.1 Sandoz Company Information
  87. 7.15.2 Sandoz Business Overview
  88. 7.15.3 Sandoz Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
  90. 7.15.5 Sandoz Recent Developments
  91. 7.16 Pfizer
  92. 7.16.1 Pfizer Company Information
  93. 7.16.2 Pfizer Business Overview
  94. 7.16.3 Pfizer Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
  96. 7.16.5 Pfizer Recent Developments
  97. 7.17 Kashiv BioSciences
  98. 7.17.1 Kashiv BioSciences Company Information
  99. 7.17.2 Kashiv BioSciences Business Overview
  100. 7.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
  102. 7.17.5 Kashiv BioSciences Recent Developments
  103. 7.18 Amgen
  104. 7.18.1 Amgen Company Information
  105. 7.18.2 Amgen Business Overview
  106. 7.18.3 Amgen Filgrastim and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
  108. 7.18.5 Amgen Recent Developments
8 North America
  1. 8.1 North America Filgrastim and Biosimilars Market Size by Type
  2. 8.1.1 North America Filgrastim and Biosimilars Revenue by Type (2021-2032)
  3. 8.1.2 North America Filgrastim and Biosimilars Sales by Type (2021-2032)
  4. 8.1.3 North America Filgrastim and Biosimilars Price by Type (2021-2032)
  5. 8.2 North America Filgrastim and Biosimilars Market Size by Application
  6. 8.2.1 North America Filgrastim and Biosimilars Revenue by Application (2021-2032)
  7. 8.2.2 North America Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 8.2.3 North America Filgrastim and Biosimilars Price by Application (2021-2032)
  9. 8.3 North America Filgrastim and Biosimilars Market Size by Country
  10. 8.3.1 North America Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Filgrastim and Biosimilars Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Filgrastim and Biosimilars Market Size by Type
  2. 9.1.1 Europe Filgrastim and Biosimilars Revenue by Type (2021-2032)
  3. 9.1.2 Europe Filgrastim and Biosimilars Sales by Type (2021-2032)
  4. 9.1.3 Europe Filgrastim and Biosimilars Price by Type (2021-2032)
  5. 9.2 Europe Filgrastim and Biosimilars Market Size by Application
  6. 9.2.1 Europe Filgrastim and Biosimilars Revenue by Application (2021-2032)
  7. 9.2.2 Europe Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 9.2.3 Europe Filgrastim and Biosimilars Price by Application (2021-2032)
  9. 9.3 Europe Filgrastim and Biosimilars Market Size by Country
  10. 9.3.1 Europe Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Filgrastim and Biosimilars Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Filgrastim and Biosimilars Market Size by Type
  2. 10.1.1 China Filgrastim and Biosimilars Revenue by Type (2021-2032)
  3. 10.1.2 China Filgrastim and Biosimilars Sales by Type (2021-2032)
  4. 10.1.3 China Filgrastim and Biosimilars Price by Type (2021-2032)
  5. 10.2 China Filgrastim and Biosimilars Market Size by Application
  6. 10.2.1 China Filgrastim and Biosimilars Revenue by Application (2021-2032)
  7. 10.2.2 China Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 10.2.3 China Filgrastim and Biosimilars Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Filgrastim and Biosimilars Market Size by Type
  2. 11.1.1 Asia Filgrastim and Biosimilars Revenue by Type (2021-2032)
  3. 11.1.2 Asia Filgrastim and Biosimilars Sales by Type (2021-2032)
  4. 11.1.3 Asia Filgrastim and Biosimilars Price by Type (2021-2032)
  5. 11.2 Asia Filgrastim and Biosimilars Market Size by Application
  6. 11.2.1 Asia Filgrastim and Biosimilars Revenue by Application (2021-2032)
  7. 11.2.2 Asia Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 11.2.3 Asia Filgrastim and Biosimilars Price by Application (2021-2032)
  9. 11.3 Asia Filgrastim and Biosimilars Market Size by Country
  10. 11.3.1 Asia Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Filgrastim and Biosimilars Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Filgrastim and Biosimilars Market Size by Type
  2. 12.1.1 SAMEA Filgrastim and Biosimilars Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Filgrastim and Biosimilars Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Filgrastim and Biosimilars Price by Type (2021-2032)
  5. 12.2 SAMEA Filgrastim and Biosimilars Market Size by Application
  6. 12.2.1 SAMEA Filgrastim and Biosimilars Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Filgrastim and Biosimilars Price by Application (2021-2032)
  9. 12.3 SAMEA Filgrastim and Biosimilars Market Size by Country
  10. 12.3.1 SAMEA Filgrastim and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Filgrastim and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Filgrastim and Biosimilars Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Filgrastim and Biosimilars Value Chain Analysis
  2. 13.1.1 Filgrastim and Biosimilars Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Filgrastim and Biosimilars Production Mode & Process
  6. 13.2 Filgrastim and Biosimilars Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Filgrastim and Biosimilars Distributors
  9. 13.2.3 Filgrastim and Biosimilars Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst